company background image
RPTX logo

Repare Therapeutics NasdaqGS:RPTX Stock Report

Last Price

US$3.12

Market Cap

US$132.4m

7D

-12.1%

1Y

-69.7%

Updated

26 May, 2024

Data

Company Financials +

Repare Therapeutics Inc.

NasdaqGS:RPTX Stock Report

Market Cap: US$132.4m

RPTX Stock Overview

A clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States.

RPTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Repare Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Repare Therapeutics
Historical stock prices
Current Share PriceUS$3.12
52 Week HighUS$13.85
52 Week LowUS$2.98
Beta0.70
1 Month Change-2.50%
3 Month Change-52.87%
1 Year Change-69.71%
3 Year Change-90.35%
5 Year Changen/a
Change since IPO-89.87%

Recent News & Updates

Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues

May 01
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues

Recent updates

Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues

May 01
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues

Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet

Mar 12
Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet

We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully

Feb 15
We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth

Dec 20
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth

Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

Oct 24
Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)

Aug 14
New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)

Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week

May 14
Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week

Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results

May 12
Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results

Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough

May 08
Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough

Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%

Mar 03
Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Oct 27
Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners

Sep 07

Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M

Aug 04

Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go

Jun 27

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Jun 24
Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans

Mar 02
Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans

We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn

Oct 14
We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn

We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth

Apr 16
We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth

Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?

Mar 12
Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?

Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?

Feb 08
Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?

Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies

Dec 28

Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently

Dec 21
Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently

We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth

Nov 19
We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth

Shareholder Returns

RPTXUS BiotechsUS Market
7D-12.1%-1.7%-0.3%
1Y-69.7%7.1%25.4%

Return vs Industry: RPTX underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: RPTX underperformed the US Market which returned 25.4% over the past year.

Price Volatility

Is RPTX's price volatile compared to industry and market?
RPTX volatility
RPTX Average Weekly Movement9.2%
Biotechs Industry Average Movement11.3%
Market Average Movement5.9%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market2.8%

Stable Share Price: RPTX's share price has been volatile over the past 3 months.

Volatility Over Time: RPTX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016179Lloyd Segalwww.reparerx.com

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company’s lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Repare Therapeutics Inc. Fundamentals Summary

How do Repare Therapeutics's earnings and revenue compare to its market cap?
RPTX fundamental statistics
Market capUS$132.43m
Earnings (TTM)-US$45.69m
Revenue (TTM)US$97.86m

1.4x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RPTX income statement (TTM)
RevenueUS$97.86m
Cost of RevenueUS$132.34m
Gross Profit-US$34.48m
Other ExpensesUS$11.21m
Earnings-US$45.69m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.08
Gross Margin-35.24%
Net Profit Margin-46.69%
Debt/Equity Ratio0%

How did RPTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.